<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01185821</url>
  </required_header>
  <id_info>
    <org_study_id>CBAF312A2201E1</org_study_id>
    <secondary_id>2009-014392-51</secondary_id>
    <nct_id>NCT01185821</nct_id>
  </id_info>
  <brief_title>Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis</brief_title>
  <official_title>A Dose Blinded Extension Study to the CBAF312A2201 Study to Evaluate Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally Once Daily in Patients With Relapsing-remitting Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study consisted of a two year dose blinded phase during which patients received one of
      five doses of siponimod (10, 2, 1.25, 0.5 or 0.25mg) following which patients were switched
      to open label treatment with siponimod 2mg for approximately a further 3 years. It will
      provide data on long term safety, tolerability and efficacy of siponimod in the RRMS patient
      population
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was prematurely discontinued after approximately 5 years. The decision to
      prematurely discontinue the study was not taken due to safety-related concerns, rather due to
      a decision to focus the development of siponimod in MS on a different population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 30, 2010</start_date>
  <completion_date type="Actual">October 10, 2016</completion_date>
  <primary_completion_date type="Actual">October 10, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This extension study was originally set up as a 2 year dose-blinded extension study to maintain blinding of ongoing Core study. Study was later amended to include a subsequent Open-Label treatment phase after Core study was unblinded. During the Dose-Blinded phase of the extension study patients received the same dose from the Core study. Patients who received placebo in Period 1 during the Core Study were equally randomized to 1 of the 3 active doses of siponimod used during Period 1 (0.5, 2.0, or 10 mg) and patients who received placebo in Period 2 were equally randomized to 1 of the 2 active doses of siponimod used during Period 2 (0.25 mg or 1.25 mg).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Masking continued during the double blind period of extension only.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Total Number of Adverse Events During Evaluation of Long Term Safety and Tolerability of BAF312A in Extension Study.</measure>
    <time_frame>Baseline up to approximately 5 years</time_frame>
    <description>Refer to adverse events for complete listing of serious adverse events and other adverse events. Adverse events of interest were presented in separate tables. There were no reports of macular edema.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Cardiac Conduction Abnormalities During the Titration Phase of the Study (Without Washout)</measure>
    <time_frame>Baseline Extension up to day 10</time_frame>
    <description>Number of patients with abnormal ECG conduction findings during dose-blinded titration at any visit post-dose, by type of abnormality and treatment (Extension Set). Number analyzed represent participants who had ECG results. Washout was defined as not being on treatment drug between Core and Extension for &gt;7 days. Abbreviation: Con=conduction, IVCD=intraventricular conduction defect , WPW=Wolff-Parkinson-White syndrome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Cardiac Conduction-IVCD Abnormality During the Titration Phase of the Study (With Washout)</measure>
    <time_frame>Baseline Extension up to day 10</time_frame>
    <description>Number of patients with abnormal ECG conduction findings during dose-blinded titration at any visit post-dose, by type of abnormality and treatment (Extension Set). Number analyzed represent participants who had ECG results. Washout was defined as not being on treatment drug between Core and Extension for &gt;7 days. Abbreviations: washout = WO, Con=conduction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Changes in Blood Pressure for Overall Extension Study. (Extension Analysis Set)</measure>
    <time_frame>Baseline Extension up to approximately 5 years</time_frame>
    <description>Sitting blood pressure was measured in triplicate. The categories of notably low and high values and changes are presented for systolic (SBP) and diastolic (DBP). Multiple occurrences for a patient are counted as one occurrence in this table.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Viral Infections of Interest Greater or Equal to 5% in Any Dose Group (Extension Set)</measure>
    <time_frame>Baseline Extension up to approximately 5 years</time_frame>
    <description>Most infections were clinical diagnoses and were not confirmed by microbiology / virologic investigations. A patient with multiple occurrences of an infection for a preferred term is counted only once in each specific category.
Events identified as infections by the Investigator and defined as an AE with onset on or after the first dose of Extension Study drug up to and including 30 days after the date of the last dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Dermatologic Alterations - Basal Cell Carcinoma (Extension Set)</measure>
    <time_frame>Baseline Extension up to approximately 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Relapses in One Year - Annualized Relapse Rates for Overall Extension Study (ARR) (Extension Set)</measure>
    <time_frame>Baseline extension up to approximately 5 years</time_frame>
    <description>Group level ARR (raw) is calculated as the total number of relapses for all the patients in the treatment group divided by the total number of days on study for all patients in the group and multiplied by 365.25 to obtain the annual rate.
Model estimates are based on a negative binomial regression model, adjusted for treatment group, age, baseline EDSS, baseline number of Gd-enhanced T1 lesions and number of relapses in previous 2 years as covariates, with log(time on study in years) as the offset variable, using the log link.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Free of Magnetic Resonance Imaging (MRI) Identified Disease Activity at Any Scan During Extension Study (Extension Set)</measure>
    <time_frame>Baseline Extension up to approximately 5 years</time_frame>
    <description>Free of MRI disease activity is defined as free of Gadolinium enhanced T1 lesions at any scan; free of new or enlarging T2 lesions at any scan: free of both gadolinium enhanced T1 lesions and new or enlarging T2 lesions at any scan. Number of patients analyzed = patients with at least one MRI scan during the specified time period. New lesions at a specific visit are assessed relative to the previous scheduled visit scan.
No imputation of missing scans is performed. As a result missing scans can lead to an overestimation of the proportion of patients free of a specific MRI activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Free of Confirmed Disability Progression in Extension Study (Extension Set)</measure>
    <time_frame>Baseline Extension up to approximately 5 years</time_frame>
    <description>Six-month disability progression was defined relative to extension baseline EDSS score: 1.5 point increase in patients with baseline EDSS score of 0, 1.0 increase in patients with baseline EDSS score of between 0.5 to 5.0, inclusive and 0.5 increase in patients with baseline EDSS score of â‰¥ 5.5. The criteria for 6-month disability progression included detection of onset of progression and confirmation of progression for a period of at least 6 months.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">185</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>BAF312 10 mg/2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAF312 2 mg/2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAF312 1.25 mg/2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAF312 .5 mg/2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>.5 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAF312 .25 mg/2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAF312</intervention_name>
    <description>BAF312 was supplied in film-coated tablets in strengths of 5, 4 ,2, 1, .5 and .25 mg. The actual doses taken were 10, 2, 1.25, .5 and .25 mg taken orally once a day.</description>
    <arm_group_label>BAF312 10 mg/2 mg</arm_group_label>
    <arm_group_label>BAF312 2 mg/2 mg</arm_group_label>
    <arm_group_label>BAF312 1.25 mg/2 mg</arm_group_label>
    <arm_group_label>BAF312 .5 mg/2 mg</arm_group_label>
    <arm_group_label>BAF312 .25 mg/2 mg</arm_group_label>
    <other_name>siponimod</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients completed the core study BAF312A2201

          -  Written informed consent provided before any assessment of the extension study

          -  Female patients at risk of becoming pregnant must have a negative pregnancy test and
             use simultaneously two forms of effective contraception

        Exclusion Criteria:

          -  Newly diagnosed systemic disease other than MS (which may require immunosuppressive
             treatment)

          -  Malignancies, diabetes, significant cardiovascular and pulmonary diseases and
             conditions

          -  Active infections
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>56 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pompano Beach</city>
        <state>Florida</state>
        <zip>33060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49525</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J9J 0A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00930</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tampere</city>
        <zip>FIN-33520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ibbenbueren</city>
        <zip>49477</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1076</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Veszprem</city>
        <zip>H-8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montichiari</city>
        <state>BS</state>
        <zip>25018</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chieti</city>
        <state>CH</state>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-324</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-957</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kazan</city>
        <zip>420103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>125367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>127018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lugano</city>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zuerich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Haseki / Istanbul</city>
        <zip>34096</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kocaeli</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://jamanetwork.com/journals/jamaneurology/fullarticle/2532101</url>
    <description>Publication from the Journal of the American Medical Association (JAMA) - Neurology</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2010</study_first_submitted>
  <study_first_submitted_qc>August 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2010</study_first_posted>
  <results_first_submitted>October 10, 2017</results_first_submitted>
  <results_first_submitted_qc>November 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 12, 2017</results_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BAF312</keyword>
  <keyword>siponimod</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Relapsing remitting Multiple Sclerosis</keyword>
  <keyword>Demyelinating Autoimmune Diseases</keyword>
  <keyword>MS</keyword>
  <keyword>RRMS</keyword>
  <keyword>inflammatory disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All patients enrolled in the Extension study had completed the Core study. All patients underwent a 10 day titration at the start of the dose blinded phase of the study</recruitment_details>
      <pre_assignment_details>During the double blind phase of the extension study patients received the same dose from the Core study. Placebo patients from Core Period 1 were randomized to 0.5, 2 or 10mg, those from Period 2 were randomized to 0.25 or 1.25 mg. All patients received 2mg in Open Label phase (.5 and .25mg were titrated up to 2mg)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>BAF312 10 mg/2 mg</title>
          <description>10 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
        </group>
        <group group_id="P2">
          <title>BAF312 2 mg/2 mg</title>
          <description>2 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
        </group>
        <group group_id="P3">
          <title>BAF312 1.25 mg/2 mg</title>
          <description>1.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
        </group>
        <group group_id="P4">
          <title>BAF312 .5 mg/2 mg</title>
          <description>.5 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
        </group>
        <group group_id="P5">
          <title>BAF312 .25 mg/2 mg</title>
          <description>.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="43"/>
                <participants group_id="P4" count="29"/>
                <participants group_id="P5" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Patients With Washout</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="39"/>
                <participants group_id="P4" count="29"/>
                <participants group_id="P5" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Patients Without Washout</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Patients on Placebo in Core</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="23"/>
                <participants group_id="P5" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Abnormal laboratory value(s)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal test procedure result</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Condition no longer required study drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Extension set consisted of all patients who received at least one dose of Extension study drug who do not have a major protocol deviation.</population>
      <group_list>
        <group group_id="B1">
          <title>BAF312 10 mg/2 mg</title>
          <description>10 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
        </group>
        <group group_id="B2">
          <title>BAF312 2 mg/2 mg</title>
          <description>2 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
        </group>
        <group group_id="B3">
          <title>BAF312 1.25 mg/2 mg</title>
          <description>1.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
        </group>
        <group group_id="B4">
          <title>BAF312 .5 mg/2 mg</title>
          <description>.5 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
        </group>
        <group group_id="B5">
          <title>BAF312 .25 mg/2 mg</title>
          <description>.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="43"/>
            <count group_id="B4" value="29"/>
            <count group_id="B5" value="50"/>
            <count group_id="B6" value="184"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.8" spread="9.09"/>
                    <measurement group_id="B2" value="35.1" spread="9.16"/>
                    <measurement group_id="B3" value="34.0" spread="7.57"/>
                    <measurement group_id="B4" value="35.2" spread="9.10"/>
                    <measurement group_id="B5" value="37.2" spread="8.42"/>
                    <measurement group_id="B6" value="35.7" spread="8.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="41"/>
                    <measurement group_id="B6" value="130"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Expanded disability status scale (EDSS)</title>
          <description>Disability progression was assessed based on the EDSS scores ranging from 0 (normal) to 10 (death due to MS)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.03" spread="0.960"/>
                    <measurement group_id="B2" value="2.19" spread="1.278"/>
                    <measurement group_id="B3" value="1.95" spread="1.096"/>
                    <measurement group_id="B4" value="1.88" spread="1.374"/>
                    <measurement group_id="B5" value="2.22" spread="1.258"/>
                    <measurement group_id="B6" value="2.07" spread="1.190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Number of Adverse Events During Evaluation of Long Term Safety and Tolerability of BAF312A in Extension Study.</title>
        <description>Refer to adverse events for complete listing of serious adverse events and other adverse events. Adverse events of interest were presented in separate tables. There were no reports of macular edema.</description>
        <time_frame>Baseline up to approximately 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BAF312 10 mg/2 mg</title>
            <description>10 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
          <group group_id="O2">
            <title>BAF312 2 mg/2 mg</title>
            <description>2 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
          <group group_id="O3">
            <title>BAF312 1.25 mg/2 mg</title>
            <description>1.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
          <group group_id="O4">
            <title>BAF312 .5 mg/2 mg</title>
            <description>.5 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
          <group group_id="O5">
            <title>BAF312 .25 mg/2 mg</title>
            <description>.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Adverse Events During Evaluation of Long Term Safety and Tolerability of BAF312A in Extension Study.</title>
          <description>Refer to adverse events for complete listing of serious adverse events and other adverse events. Adverse events of interest were presented in separate tables. There were no reports of macular edema.</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Cardiac Conduction Abnormalities During the Titration Phase of the Study (Without Washout)</title>
        <description>Number of patients with abnormal ECG conduction findings during dose-blinded titration at any visit post-dose, by type of abnormality and treatment (Extension Set). Number analyzed represent participants who had ECG results. Washout was defined as not being on treatment drug between Core and Extension for &gt;7 days. Abbreviation: Con=conduction, IVCD=intraventricular conduction defect , WPW=Wolff-Parkinson-White syndrome</description>
        <time_frame>Baseline Extension up to day 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BAF312 10 mg/2 mg</title>
            <description>10 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
          <group group_id="O2">
            <title>BAF312 2 mg/2 mg</title>
            <description>2 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
          <group group_id="O3">
            <title>BAF312 1.25 mg/2 mg</title>
            <description>1.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
          <group group_id="O4">
            <title>BAF312 .5 mg/2 mg</title>
            <description>.5 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
          <group group_id="O5">
            <title>BAF312 .25 mg/2 mg</title>
            <description>.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Conduction Abnormalities During the Titration Phase of the Study (Without Washout)</title>
          <description>Number of patients with abnormal ECG conduction findings during dose-blinded titration at any visit post-dose, by type of abnormality and treatment (Extension Set). Number analyzed represent participants who had ECG results. Washout was defined as not being on treatment drug between Core and Extension for &gt;7 days. Abbreviation: Con=conduction, IVCD=intraventricular conduction defect , WPW=Wolff-Parkinson-White syndrome</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Conduction-Prolonged QTc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conduction - IVCD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conduction - AV Mobitz I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Con:1st degree AV block</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conduction - WPW</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Cardiac Conduction-IVCD Abnormality During the Titration Phase of the Study (With Washout)</title>
        <description>Number of patients with abnormal ECG conduction findings during dose-blinded titration at any visit post-dose, by type of abnormality and treatment (Extension Set). Number analyzed represent participants who had ECG results. Washout was defined as not being on treatment drug between Core and Extension for &gt;7 days. Abbreviations: washout = WO, Con=conduction</description>
        <time_frame>Baseline Extension up to day 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BAF312 .25 mg/2 mg</title>
            <description>.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Conduction-IVCD Abnormality During the Titration Phase of the Study (With Washout)</title>
          <description>Number of patients with abnormal ECG conduction findings during dose-blinded titration at any visit post-dose, by type of abnormality and treatment (Extension Set). Number analyzed represent participants who had ECG results. Washout was defined as not being on treatment drug between Core and Extension for &gt;7 days. Abbreviations: washout = WO, Con=conduction</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Changes in Blood Pressure for Overall Extension Study. (Extension Analysis Set)</title>
        <description>Sitting blood pressure was measured in triplicate. The categories of notably low and high values and changes are presented for systolic (SBP) and diastolic (DBP). Multiple occurrences for a patient are counted as one occurrence in this table.</description>
        <time_frame>Baseline Extension up to approximately 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BAF312 10 mg/2 mg</title>
            <description>10 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
          <group group_id="O2">
            <title>BAF312 2 mg/2 mg</title>
            <description>2 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
          <group group_id="O3">
            <title>BAF312 1.25 mg/2 mg</title>
            <description>1.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
          <group group_id="O4">
            <title>BAF312 .5 mg/2 mg</title>
            <description>.5 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
          <group group_id="O5">
            <title>BAF312 .25 mg/2 mg</title>
            <description>.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Changes in Blood Pressure for Overall Extension Study. (Extension Analysis Set)</title>
          <description>Sitting blood pressure was measured in triplicate. The categories of notably low and high values and changes are presented for systolic (SBP) and diastolic (DBP). Multiple occurrences for a patient are counted as one occurrence in this table.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP Low: â‰¤ 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP â‰¥ 20 decrease from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP High: â‰¥ 160</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP â‰¥ 20 increase from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP Low: â‰¤ 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP â‰¥ 15 decrease from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP High: â‰¥ 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP â‰¥ 15 increase from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Viral Infections of Interest Greater or Equal to 5% in Any Dose Group (Extension Set)</title>
        <description>Most infections were clinical diagnoses and were not confirmed by microbiology / virologic investigations. A patient with multiple occurrences of an infection for a preferred term is counted only once in each specific category.
Events identified as infections by the Investigator and defined as an AE with onset on or after the first dose of Extension Study drug up to and including 30 days after the date of the last dose</description>
        <time_frame>Baseline Extension up to approximately 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BAF312 10 mg/2 mg</title>
            <description>10 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
          <group group_id="O2">
            <title>BAF312 2 mg/2 mg</title>
            <description>2 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
          <group group_id="O3">
            <title>BAF312 1.25 mg/2 mg</title>
            <description>1.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
          <group group_id="O4">
            <title>BAF312 .5 mg/2 mg</title>
            <description>.5 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
          <group group_id="O5">
            <title>BAF312 .25 mg/2 mg</title>
            <description>.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Viral Infections of Interest Greater or Equal to 5% in Any Dose Group (Extension Set)</title>
          <description>Most infections were clinical diagnoses and were not confirmed by microbiology / virologic investigations. A patient with multiple occurrences of an infection for a preferred term is counted only once in each specific category.
Events identified as infections by the Investigator and defined as an AE with onset on or after the first dose of Extension Study drug up to and including 30 days after the date of the last dose</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oral herpes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Herpes zoster</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Dermatologic Alterations - Basal Cell Carcinoma (Extension Set)</title>
        <time_frame>Baseline Extension up to approximately 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BAF312 10 mg/2 mg</title>
            <description>10 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
          <group group_id="O2">
            <title>BAF312 2 mg/2 mg</title>
            <description>2 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
          <group group_id="O3">
            <title>BAF312 1.25 mg/2 mg</title>
            <description>1.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
          <group group_id="O4">
            <title>BAF312 .5 mg/2 mg</title>
            <description>.5 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
          <group group_id="O5">
            <title>BAF312 .25 mg/2 mg</title>
            <description>.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Dermatologic Alterations - Basal Cell Carcinoma (Extension Set)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Relapses in One Year - Annualized Relapse Rates for Overall Extension Study (ARR) (Extension Set)</title>
        <description>Group level ARR (raw) is calculated as the total number of relapses for all the patients in the treatment group divided by the total number of days on study for all patients in the group and multiplied by 365.25 to obtain the annual rate.
Model estimates are based on a negative binomial regression model, adjusted for treatment group, age, baseline EDSS, baseline number of Gd-enhanced T1 lesions and number of relapses in previous 2 years as covariates, with log(time on study in years) as the offset variable, using the log link.</description>
        <time_frame>Baseline extension up to approximately 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BAF312 10 mg/2 mg</title>
            <description>10 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
          <group group_id="O2">
            <title>BAF312 2 mg/2 mg</title>
            <description>2 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
          <group group_id="O3">
            <title>BAF312 1.25 mg/2 mg</title>
            <description>1.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
          <group group_id="O4">
            <title>BAF312 .5 mg/2 mg</title>
            <description>.5 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
          <group group_id="O5">
            <title>BAF312 .25 mg/2 mg</title>
            <description>.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Relapses in One Year - Annualized Relapse Rates for Overall Extension Study (ARR) (Extension Set)</title>
          <description>Group level ARR (raw) is calculated as the total number of relapses for all the patients in the treatment group divided by the total number of days on study for all patients in the group and multiplied by 365.25 to obtain the annual rate.
Model estimates are based on a negative binomial regression model, adjusted for treatment group, age, baseline EDSS, baseline number of Gd-enhanced T1 lesions and number of relapses in previous 2 years as covariates, with log(time on study in years) as the offset variable, using the log link.</description>
          <units>Group level ARR</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" lower_limit="0.11" upper_limit="0.31"/>
                    <measurement group_id="O2" value="0.15" lower_limit="0.08" upper_limit="0.26"/>
                    <measurement group_id="O3" value="0.16" lower_limit="0.10" upper_limit="0.26"/>
                    <measurement group_id="O4" value="0.19" lower_limit="0.11" upper_limit="0.33"/>
                    <measurement group_id="O5" value="0.22" lower_limit="0.14" upper_limit="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Free of Magnetic Resonance Imaging (MRI) Identified Disease Activity at Any Scan During Extension Study (Extension Set)</title>
        <description>Free of MRI disease activity is defined as free of Gadolinium enhanced T1 lesions at any scan; free of new or enlarging T2 lesions at any scan: free of both gadolinium enhanced T1 lesions and new or enlarging T2 lesions at any scan. Number of patients analyzed = patients with at least one MRI scan during the specified time period. New lesions at a specific visit are assessed relative to the previous scheduled visit scan.
No imputation of missing scans is performed. As a result missing scans can lead to an overestimation of the proportion of patients free of a specific MRI activity.</description>
        <time_frame>Baseline Extension up to approximately 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BAF312 10 mg/2 mg</title>
            <description>10 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
          <group group_id="O2">
            <title>BAF312 2 mg/2 mg</title>
            <description>2 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
          <group group_id="O3">
            <title>BAF312 1.25 mg/2 mg</title>
            <description>1.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
          <group group_id="O4">
            <title>BAF312 .5 mg/2 mg</title>
            <description>.5 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
          <group group_id="O5">
            <title>BAF312 .25 mg/2 mg</title>
            <description>.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Free of Magnetic Resonance Imaging (MRI) Identified Disease Activity at Any Scan During Extension Study (Extension Set)</title>
          <description>Free of MRI disease activity is defined as free of Gadolinium enhanced T1 lesions at any scan; free of new or enlarging T2 lesions at any scan: free of both gadolinium enhanced T1 lesions and new or enlarging T2 lesions at any scan. Number of patients analyzed = patients with at least one MRI scan during the specified time period. New lesions at a specific visit are assessed relative to the previous scheduled visit scan.
No imputation of missing scans is performed. As a result missing scans can lead to an overestimation of the proportion of patients free of a specific MRI activity.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Free of Gd-enhanced T1 lesions at any scan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.1"/>
                    <measurement group_id="O2" value="57.7"/>
                    <measurement group_id="O3" value="58.1"/>
                    <measurement group_id="O4" value="44.8"/>
                    <measurement group_id="O5" value="66.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free of new/enlarging T2 lesions at any scan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3"/>
                    <measurement group_id="O2" value="42.3"/>
                    <measurement group_id="O3" value="46.5"/>
                    <measurement group_id="O4" value="20.7"/>
                    <measurement group_id="O5" value="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free of Gd-enhanced T1 and new enlarged T2 lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3"/>
                    <measurement group_id="O2" value="42.3"/>
                    <measurement group_id="O3" value="44.2"/>
                    <measurement group_id="O4" value="20.7"/>
                    <measurement group_id="O5" value="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Free of Confirmed Disability Progression in Extension Study (Extension Set)</title>
        <description>Six-month disability progression was defined relative to extension baseline EDSS score: 1.5 point increase in patients with baseline EDSS score of 0, 1.0 increase in patients with baseline EDSS score of between 0.5 to 5.0, inclusive and 0.5 increase in patients with baseline EDSS score of â‰¥ 5.5. The criteria for 6-month disability progression included detection of onset of progression and confirmation of progression for a period of at least 6 months.</description>
        <time_frame>Baseline Extension up to approximately 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BAF312 10 mg/2 mg</title>
            <description>10 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
          <group group_id="O2">
            <title>BAF312 2 mg/2 mg</title>
            <description>2 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
          <group group_id="O3">
            <title>BAF312 1.25 mg/2 mg</title>
            <description>1.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
          <group group_id="O4">
            <title>BAF312 .5 mg/2 mg</title>
            <description>.5 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
          <group group_id="O5">
            <title>BAF312 .25 mg/2 mg</title>
            <description>.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Free of Confirmed Disability Progression in Extension Study (Extension Set)</title>
          <description>Six-month disability progression was defined relative to extension baseline EDSS score: 1.5 point increase in patients with baseline EDSS score of 0, 1.0 increase in patients with baseline EDSS score of between 0.5 to 5.0, inclusive and 0.5 increase in patients with baseline EDSS score of â‰¥ 5.5. The criteria for 6-month disability progression included detection of onset of progression and confirmation of progression for a period of at least 6 months.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.3" lower_limit="56.0" upper_limit="88.7"/>
                    <measurement group_id="O2" value="82.4" lower_limit="66.6" upper_limit="98.3"/>
                    <measurement group_id="O3" value="84.8" lower_limit="73.5" upper_limit="96.0"/>
                    <measurement group_id="O4" value="81.4" lower_limit="66.6" upper_limit="96.1"/>
                    <measurement group_id="O5" value="78.6" lower_limit="65.4" upper_limit="91.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) are collected from First Patient First Visit (FPFV)until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>BAF312 10/2 mg</title>
          <description>BAF312 10/2 mg</description>
        </group>
        <group group_id="E2">
          <title>BAF312 2/2 mg</title>
          <description>BAF312 2/2 mg</description>
        </group>
        <group group_id="E3">
          <title>BAF312 1.25/2 mg</title>
          <description>BAF312 1.25/2 mg</description>
        </group>
        <group group_id="E4">
          <title>BAF312 0.5/2 mg</title>
          <description>BAF312 0.5/2 mg</description>
        </group>
        <group group_id="E5">
          <title>BAF312 0.25/2 mg</title>
          <description>BAF312 0.25/2 mg</description>
        </group>
        <group group_id="E6">
          <title>All Patients</title>
          <description>All patients</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="31" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Splenic cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Submandibular mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Smear cervix abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Uterine cervical metaplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3.999</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="42" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="169" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="24" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="27" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="64" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Tinea versicolour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="30" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Fibrous histiocytoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="36" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Muscle spasticity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Catarrh</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Pigmentation disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

